Ascletis' regulatory filing for HCV Treatment danoprevir accepted by CFDA

1 January 2017

China's first oral antiviral drug, dubbed danoprevir (ASC08), for treating hepatitis C virus (HCV) has been accepted for review by the Chinese Food and Drug Administration (CFDA).

The drug requires a 12 week course of treatment. Clinical tests show it can cure 90% of HCV patients, said chief of the development team, Wu Jinzi, who set up Ascletis Pharmaceutical in 2014 in east China's Hangzhou City for pharmaceutical development and production, reported by the China state news agency Xinhua.

China has more than 8.5 million people with HCV. The hepatitis C can develop into fibrosis and cirrhosis of the liver and even liver cancer.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK